FdaApplication
NDA 207924
Identifiers
- fda_app_no: NDA207924
Properties
| Property | Value |
|---|---|
| applicant_name | ELI LILLY AND CO |
| application_type | NDA |
| approval_date | 2018-05-31 |
Revenue by product
OLUMIANT
| Period | Revenue |
|---|---|
| Q4 2024 | $1.2B |
| Q3 2024 | $250.8M |
| Q2 2024 | $227.7M |
| Q1 2024 | $217.4M |
| Q4 2023 | $1.2B |
| Q3 2023 | $231.4M |
| Q2 2023 | $218.9M |
| Q1 2023 | $228.9M |
| Q4 2022 | $1.0B |
| Q3 2022 | $182.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OLUMIANT | BARICITINIB | 4MG | TABLET;ORAL |
| OLUMIANT | BARICITINIB | 1MG | TABLET;ORAL |
| OLUMIANT | BARICITINIB | 2MG | TABLET;ORAL |
3 products